Cybin (CYBN) Begins Phase II Study on Anxiety Drug, Stock Up [Yahoo! Finance]
Cybin Inc. Common Shares (CYBN)
Company Research
Source: Yahoo! Finance
dimethyltryptamine molecule, CYB004, for the treatment of patients with generalized anxiety disorder (GAD). Per the company, the double-blind phase II CYB004-002 study will investigate the safety and efficacy of CYB004 in the given patient population. Patients will be divided into two groups. The first group of patients will receive two IM doses of CYB004, while the second group will take two low-dose control administrations of CYB004. The primary endpoint of the study is to see the change in the Hamilton Anxiety Rating Scale score from baseline at six weeks of treatment after the administration of the second dose. Meanwhile, the Montgomery-Asberg Depression Rating scale depression assessment, safety assessments, psychedelic experience assessment and the quality of life assessment remain the other endpoints of the above study. Top-line data from the CYB004-002 study is expected to be announced in the fourth quarter of 2024. Data from the study is likely to establish the proof
Show less
Read more
Impact Snapshot
Event Time:
CYBN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CYBN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CYBN alerts
High impacting Cybin Inc. Common Shares news events
Weekly update
A roundup of the hottest topics
CYBN
News
- Cybin to Participate at the 27th Annual Milken Institute Global ConferenceBusiness Wire
- Cybin Announces Publication of Research Manuscript in the Journal of Medicinal Chemistry [Yahoo! Finance]Yahoo! Finance
- Cybin Announces Publication of Research Manuscript in the Journal of Medicinal ChemistryBusiness Wire
- Cedar Clinical Research selected as clinical research site for Cybin's Phase 3 Study of CYB003 [Yahoo! Finance]Yahoo! Finance
- Cybin Announces Grant of Additional U.S. Patent in Support of its CYB003 Breakthrough Therapy Program for Major Depressive Disorder [Yahoo! Finance]Yahoo! Finance
CYBN
Sec Filings
- 4/25/24 - Form 6-K
- 4/22/24 - Form D
- 4/18/24 - Form 6-K
- CYBN's page on the SEC website